ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
Stock Information for Greenpro Capital Corp.
Loading
Please wait while we load your information from QuoteMedia.